Biocytogen Pharmaceuticals Beijing (SHA:688796, HKG:2315) raised the total investment for its drug early-stage research and development service platform construction project to 461.6 million yuan from 453.6 million yuan, according to a Thursday filing with the Shanghai bourse.
The internal investment structure will shift, cutting construction engineering payment by 254.1 million yuan while adding 135 million yuan for decoration, 119.1 million yuan for equipment, and 8 million yuan for site leasing.
The project completion date is extended to June 30, 2027, from Dec. 31, 2026.
Shares of the pharmaceutical company rose 6% in recent trade on the Hong Kong bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.